House passes several new bipartisan cybersecurity bills

The U.S. House of Representatives passed four bills this week aimed at bolstering cybersecurity efforts throughout the country. The legislation takes a variety of approaches to strengthening public entities’ response to cyber threats.    “Cyber attacks have increased at a rapid pace this year and pose a persistent threat to our national security,” said Committee… Read More »

NIH ‘very concerned’ about serious side effect in AstraZeneca coronavirus vaccine trial

“The highest levels of NIH are very concerned,” said Dr. Avindra Nath, intramural clinical director and a leader of viral research at the National Institute for Neurological Disorders and Stroke, an NIH division. “Everyone’s hopes are on a vaccine, and if you have a major complication the whole thing could get derailed.” A great deal… Read More »

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) BOSTON, July 20, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in… Read More »

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Advertisement Continue reading the main story Supported by Continue reading the main story How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were… Read More »